Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.
   Google Scholar
• Hofer A, Baumgartner S, Bodner T, et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry. 2005;20(5–6):395–402. doi:10.1016/j.eurpsy.2005.02.006
   PubMed Web of Science ®Google Scholar
• Medici CR, Vestergaard CH, Hjorth P, et al. Quality of life and clinical characteristics in a nonselected sample of patients with schizophrenia. Int J Soc Psychiatry. 2016;62(1):12–20. doi:10.1177/0020764015585330
   Web of Science ®Google Scholar
• Kaskie RE, Graziano B, Ferrarelli F. Schizophrenia and sleep disorders: links, risks, and management challenges. Nat Sci Sleep. 2017;9:227–239. doi:10.2147/NSS.S121076
   PubMed Web of Science ®Google Scholar
• Bahorik AL, Satre DD, Kline-Simon AH, Weisner CM, Campbell CI. Serious mental illness and medical comorbidities: findings from an integrated health care system. J Psychosom Res. 2017;100:35–45. doi:10.1016/j.jpsychores.2017.07.004
   PubMed Web of Science ®Google Scholar
• Rempfer MV, Hamera EK, Brown CE, Cromwell RL. The relations between cognition and the independent living skill of shopping in people with schizophrenia. Psychiatry Res. 2003;117(2):103–112. doi:10.1016/s0165-1781(02)00318-9
   PubMed Web of Science ®Google Scholar
• Schennach R, Musil R, Möller H, Riedel M. Functional outcomes in schizophrenia: employment status as a metric of treatment outcome. Curr Psychiatry Rep. 2012;14(3):229–236. doi:10.1007/s11920-012-0261-3
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou C, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373. doi:10.2147/NDT.S96649
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771. doi:10.4088/JCP.15m10278
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–163. doi:10.1176/appi.ajp.2008.08030368
   PubMed Web of Science ®Google Scholar
• Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang R. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res. 2006;144(2–3):177–189. doi:10.1016/j.psychres.2006.02.006
   Web of Science ®Google Scholar
• Serretti A, Ronchi DD, Lorenzi C, Berardi D. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem. 2004;11(3):343–358. doi:10.2174/0929867043456043
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247. doi:10.1001/archpsyc.56.3.241
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Rosch DS, Sivec HJ, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv. 2002;53(10):1319–1321. doi:10.1176/appi.ps.53.10.1319
   Web of Science ®Google Scholar
• Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47–53. doi:10.4088/jcp.v69n0107
   PubMed Web of Science ®Google Scholar
• Kikkert MJ, Schene AH, Koeter MW, et al. Medication adherence in schizophrenia: exploring patients’, carers’ and professionals’ views. Schizophr Bull (Bp). 2006;32(4):786–794. doi:10.1093/schbul/sbl011
   PubMed Web of Science ®Google Scholar
• Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry. 2004;19(7):415–422. doi:10.1016/j.eurpsy.2004.06.031
   PubMed Web of Science ®Google Scholar
• Draine J, Solomon P. Explaining attitudes toward medication compliance among a seriously mentally ill population. J Nerv Ment Dis. 1994;182(1):50–54. doi:10.1097/00005053-199401000-00009
   Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134. doi:10.1080/13696998.2017.1379412
   PubMed Web of Science ®Google Scholar
• Song X, El Khoury AC, Brouillette M, Smith D, Joshi K. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. J Med Econ. 2019;22(11):1105–1112. doi:10.1080/13696998.2019.1615927
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–1180. doi:10.2147/PPA.S53795
   PubMed Web of Science ®Google Scholar
• Keenan A, Lin D, Shepherd J, et al. Drivers of prescribing long-acting injectable antipsychotics to patients with schizophrenia. Poster presentation at: Psych Congress 2020 Virtual Experience.
   Google Scholar
• Aleman A, Kahn RS, Selten J. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60(6):565–571. doi:10.1001/archpsyc.60.6.565
   PubMed Web of Science ®Google Scholar
• McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28(12):3303–3312. doi:10.1007/s11136-019-02269-8
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8(Suppl 1):S9–S24. doi:10.1111/j.1524-4733.2005.00066.x
   PubMed Web of Science ®Google Scholar
• Bessonova L, Sajatovic M, Saucier C, et al. Treatment experiences of patients with schizophrenia: findings from a qualitative focus group study. Podium presentation at international society for pharmacoeconomics and outcomes research (ISPOR) annual meeting. New Orleans, LA. Value Health. 2019;22(Suppl 2):S33. doi:10.1016/j.jval.2019.04.009
   Google Scholar
• United States Census Bureau. Educational attainment in the United States. 2018.
   Google Scholar
• Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017;15(5):789–798. doi:10.2174/1570159X14666161208153644
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27–35. doi:10.1038/sj.mp.4002066
   PubMed Web of Science ®Google Scholar
• Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther. 2003;29(2):125–147. doi:10.1080/713847170
   PubMed Web of Science ®Google Scholar
• Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci. 2015;9:297. doi:10.3389/fnins.2015.00297
   PubMed Web of Science ®Google Scholar
• Kleinman A, Eisenberg L, Good B. Culture, illness, and care: clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978;88(2):251–258. doi:10.7326/0003-4819-88-2-251
   PubMed Web of Science ®Google Scholar
• Palijan TŽ, Kovačević D, Vlastelica M, Dadić-Hero E, Sarilar M. Quality of life of persons suffering from schizophrenia, psoriasis and physical disabilities.  Psychiatr Danub. 2017;29(1):60–65. doi:10.24869/psyd.2017.60
   Google Scholar
• Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65(7):932–939. doi:10.4088/JCP.v65n0709
   Web of Science ®Google Scholar
• Bridges JF, Beusterien K, Heres S, et al. Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling. Patient Prefer Adherence. 2018;12:63–70. doi:10.2147/PPA.S152870
   PubMed Web of Science ®Google Scholar
• Levitan B, Markowitz M, Mohamed AF, et al. Patients’ preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv. 2015;66(7):719–726. doi:10.1176/appi.ps.201400188
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Stroup S, Keefe RSE, et al. Measuring outcome priorities and preferences in people with schizophrenia. Br J Psychiatry. 2005;187(6):529–536. doi:10.1192/bjp.187.6.529
   PubMedGoogle Scholar
• Rettenbacher MA, Hofer A, Eder U, et al. Compliance in schizophrenia: psychopathology, side effects, and patients’ attitudes toward the illness and medication. J Clin Psychiatry. 2004;65(9):1211–1218. doi:10.4088/jcp.v65n0908
   PubMed Web of Science ®Google Scholar
• Miller BJ, Stewart A, Schrimsher J, Peeples D, Buckley PF. How connected are people with schizophrenia? Cell phone, computer, email, and social media use. Psychiatry Res. 2015;225(3):458–463. doi:10.1016/j.psychres.2014.11.067
   PubMed Web of Science ®Google Scholar
• Irani F, Seligman S, Kamath V, Kohler C, Gur RC. A meta-analysis of emotion perception and functional outcomes in schizophrenia. Schizophr Res. 2012;137(1–3):203–211. doi:10.1016/j.schres.2012.01.023
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. doi:10.1056/NEJMoa051688
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009.
   Google Scholar